The expression of CD44 is a hallmark of BCSCs (CD44+/CD24−) in some breast cancer subtypes, in which their phenotypes, such as self-renewal, metastasis, migration and therapeutic resistance, can lead to treatment failure and disease relapse. This evidence concerns the gene CD44 and breast carcinoma.